The Impact of Polynuclear Neutrophils' Intra-tumoral Rate and the Mutational Status in Pulmonary Adenocarcinomas on Survival

NCT ID: NCT04761640

Last Updated: 2021-02-21

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-02-28
• Study Completion Date: 2021-09-30

Brief Summary

Lung cancer is one of the most frequent cancer concerning human beings and it represents, worldwide, one of the first cause of death. Most of patients with this cancer are males and 85% of lung cancers are non-small cells type (NSCLC) with adenocarcinoma being the most common histologic subtype.

Patients with pulmonary cancer have a poor long-term prognosis with an overall 5 years of survival which is less than 25% for all stages.

The natural immune system, with polynuclear neutrophils (PNN) is involved in carcinogenesis. The impact of PNN localized within the tumor as a prognostic biomarker has not been really studied in non-small cells lung cancers.

According to some studies, an increase in the number of PNN (labelled by the CD66b antibody) within the tumor is associated to a greater risk of relapse and a poor overall survival rate.

The intra-tumoral ratio PNN over Lymphocytes T CD8 + (iNTR) is an independent factor of the poor prognosis concerning the overall survival rate and concerning risk of relapse with patients who went through a first surgery for a non-small cells lung cancer.

With this study we will initially concentrate on lung adenocarcinoma and attempt to evaluate the PNN's rate within the tumor and its impact on an overall survival rate and progression-free survival.

Secondly, we will explore the role of iNTR and the mutational profile of tumors concerning this survival.

Conditions

Pulmonary Adenocarcinoma

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Patients with stages I to III lung adenocarcinoma (TNM UICC 8ème édition)
• Patients who went through a first surgery with a lymph node dissection at the CHRU of Nancy between 01/01/2010 and 01/01/2012
• Patients included in the CRB CHRU-INSERM bronchial collection

Exclusion Criteria

• patients who received neoadjuvant therapy.
• Stage IV patients (TNM UICC 8ème édition)
• Patients whose surgical resection was incomplete

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Central Hospital, Nancy, France

OTHER

Sponsor Role: lead

Responsible Party

Guillaume GAUCHOTTE

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Guillaume GAUCHOTTE

Role: CONTACT

g.gauchotte@chru-nancy.fr

3 83 65 60 17

Other Identifiers

2020PI278

Identifier Type: -

Identifier Source: org_study_id